GSK Expects To Launch Once-Daily HIV Combo Product Ahead Of Gilead

 
• By John Rancourt

GlaxoSmithKline believes its future once-daily combination of Epivir and Ziagen will be stronger than Gilead's pending HIV combination

More from Archive

More from Pink Sheet